2016
DOI: 10.1515/revneuro-2016-0018
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: AbstractIncretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
21
0
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(24 citation statements)
references
References 268 publications
(270 reference statements)
1
21
0
2
Order By: Relevance
“…Specifically, these drugs attenuated Aβ, APP and hyperphosphorylated Tau levels, neuroinflammation, oxidative/ER stress and neuronal death in AD . These were mirrored by increased insulin degrading enzyme and insulin signalling, which may recover glucose metabolism, synaptic transmission/plasticity, neurogenesis and, ultimately, memory and cognitive performance . Similar results were recently reported with lixisenatide .…”
Section: Different Treatment Approaches Based On Pathogenesissupporting
confidence: 82%
“…Specifically, these drugs attenuated Aβ, APP and hyperphosphorylated Tau levels, neuroinflammation, oxidative/ER stress and neuronal death in AD . These were mirrored by increased insulin degrading enzyme and insulin signalling, which may recover glucose metabolism, synaptic transmission/plasticity, neurogenesis and, ultimately, memory and cognitive performance . Similar results were recently reported with lixisenatide .…”
Section: Different Treatment Approaches Based On Pathogenesissupporting
confidence: 82%
“…However, large clinical trials of the PPARγ agonist rosiglitazone failed to show primary end point benefit in AD 278 , and results are pending for a definitive clinical trial of another such agonist, pioglita-zone (NCT01931566), which has shown promising early results and better BBB penetration than rosiglitazone. Glucagon-like peptide 1 (GLP-1) - targeting drugs are another category of insulin sensitizers showing promise in AD in preclinical and early clinical trial studies 279 . However, whether these approaches improve ADRDs via their insulin-sensitizing effects on brain cells or via their other complex signalling mechanisms of action is uncertain.…”
Section: Brain Insulin Resistancementioning
confidence: 99%
“…In contrast, incretin‐based agents (GLP‐1 analogues and DPP4 inhibitors) are considered promising candidates for the treatment of neurodegenerative diseases . Research work by Holscher and colleagues (University of Lancaster) with various incretin‐based therapies has demonstrated what are described as positive cytoprotective effects, with promise for the treatment of neurodegenerative diseases such as Alzheimer's disease, and interestingly Parkinson's disease as well.…”
Section: Drugs For Diabetes: Shared Dividend For Dementiamentioning
confidence: 88%